[Clinical studies on the stimulation and suppression of the pituitary-adrenocortical system. 3. Studies on the pituitary adrenocortical suppression after long-term glucocorticoid treatment].
D015065:17-Hydroxycorticosteroids / Q000652:urine; D000309:Adrenal Insufficiency / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001249:Asthma / Q000188:drug therapy; D001623:Betamethasone / Q000008:administration & dosage; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008797:Metyrapone; D008875:Middle Aged; D010110:Oxymetholone / Q000008:administration & dosage; D010900:Pituitary Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy; D010912:Pituitary-Adrenal Function Tests; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D011239:Prednisolone / Q000008:administration & dosage; D013997:Time Factors
D015065:17-Hydroxycorticosteroids; D005938:Glucocorticoids; D000324:Adrenocorticotropic Hormone; D001623:Betamethasone; D011239:Prednisolone; D010110:Oxymetholone; D008797:Metyrapone